NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases

International Parkinson's Disease Genomics Consortium (IPDGC) and the Parkinson's Disease meta-analysis consortium

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Our objective was to design a genotyping platform that would allow rapid genetic characterization of samples in the context of genetic mutations and risk factors associated with common neurodegenerative diseases. The platform needed to be relatively affordable, rapid to deploy, and use a common and accessible technology. Central to this project, we wanted to make the content of the platform open to any investigator without restriction. In designing this array we prioritized a number of types of genetic variability for inclusion, such as known risk alleles, disease-causing mutations, putative risk alleles, and other functionally important variants. The array was primarily designed to allow rapid screening of samples for disease-causing mutations and large population studies of risk factors. Notably, an explicit aim was to make this array widely available to facilitate data sharing across and within diseases. The resulting array, NeuroX, is a remarkably cost and time effective solution for high-quality genotyping. NeuroX comprises a backbone of standard Illumina exome content of approximately 240,000 variants, and over 24,000 custom content variants focusing on neurologic diseases. Data are generated at approximately $50-$60 per sample using a 12-sample format chip and regular Infinium infrastructure; thus, genotyping is rapid and accessible to many investigators. Here, we describe the design of NeuroX, discuss the utility of NeuroX in the analyses of rare and common risk variants, and present quality control metrics and a brief primer for the analysis of NeuroX derived data.

Original languageEnglish
Pages (from-to)1605.e7-e12
JournalNeurobiology of Aging
Volume36
Issue number3
DOIs
Publication statusPublished - 1 Jan 2015
Externally publishedYes

Fingerprint

Neurodegenerative Diseases
Mutation
Alleles
Research Personnel
Exome
Information Dissemination
Nervous System Diseases
Quality Control
Technology
Costs and Cost Analysis
Population

Keywords

  • Genetics
  • Genotyping
  • Imputation
  • Meta-analysis
  • Methods
  • Neurodegeneration
  • Parkinson's

ASJC Scopus subject areas

  • Neuroscience(all)
  • Ageing
  • Clinical Neurology
  • Developmental Biology
  • Geriatrics and Gerontology

Cite this

International Parkinson's Disease Genomics Consortium (IPDGC) and the Parkinson's Disease meta-analysis consortium (2015). NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiology of Aging, 36(3), 1605.e7-e12. https://doi.org/10.1016/j.neurobiolaging.2014.07.028

NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. / International Parkinson's Disease Genomics Consortium (IPDGC) and the Parkinson's Disease meta-analysis consortium.

In: Neurobiology of Aging, Vol. 36, No. 3, 01.01.2015, p. 1605.e7-e12.

Research output: Contribution to journalArticle

International Parkinson's Disease Genomics Consortium (IPDGC) and the Parkinson's Disease meta-analysis consortium 2015, 'NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases', Neurobiology of Aging, vol. 36, no. 3, pp. 1605.e7-e12. https://doi.org/10.1016/j.neurobiolaging.2014.07.028
International Parkinson's Disease Genomics Consortium (IPDGC) and the Parkinson's Disease meta-analysis consortium. NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiology of Aging. 2015 Jan 1;36(3):1605.e7-e12. https://doi.org/10.1016/j.neurobiolaging.2014.07.028
International Parkinson's Disease Genomics Consortium (IPDGC) and the Parkinson's Disease meta-analysis consortium. / NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. In: Neurobiology of Aging. 2015 ; Vol. 36, No. 3. pp. 1605.e7-e12.
@article{4737fa707f58477dbbee80a231338f19,
title = "NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases",
abstract = "Our objective was to design a genotyping platform that would allow rapid genetic characterization of samples in the context of genetic mutations and risk factors associated with common neurodegenerative diseases. The platform needed to be relatively affordable, rapid to deploy, and use a common and accessible technology. Central to this project, we wanted to make the content of the platform open to any investigator without restriction. In designing this array we prioritized a number of types of genetic variability for inclusion, such as known risk alleles, disease-causing mutations, putative risk alleles, and other functionally important variants. The array was primarily designed to allow rapid screening of samples for disease-causing mutations and large population studies of risk factors. Notably, an explicit aim was to make this array widely available to facilitate data sharing across and within diseases. The resulting array, NeuroX, is a remarkably cost and time effective solution for high-quality genotyping. NeuroX comprises a backbone of standard Illumina exome content of approximately 240,000 variants, and over 24,000 custom content variants focusing on neurologic diseases. Data are generated at approximately $50-$60 per sample using a 12-sample format chip and regular Infinium infrastructure; thus, genotyping is rapid and accessible to many investigators. Here, we describe the design of NeuroX, discuss the utility of NeuroX in the analyses of rare and common risk variants, and present quality control metrics and a brief primer for the analysis of NeuroX derived data.",
keywords = "Genetics, Genotyping, Imputation, Meta-analysis, Methods, Neurodegeneration, Parkinson's",
author = "{International Parkinson's Disease Genomics Consortium (IPDGC) and the Parkinson's Disease meta-analysis consortium} and Nalls, {Mike A.} and Jose Bras and Hernandez, {Dena G.} and Keller, {Margaux F.} and Elisa Majounie and Renton, {Alan E.} and Mohamad Saad and Iris Jansen and Rita Guerreiro and Steven Lubbe and Vincent Plagnol and Gibbs, {J. Raphael} and Claudia Schulte and Nathan Pankratz and Margaret Sutherland and Lars Bertram and Lill, {Christina M.} and DeStefano, {Anita L.} and Tatiana Faroud and Nicholas Eriksson and Tung, {Joyce Y.} and Connor Edsall and Noah Nichols and Janet Brooks and Sampath Arepalli and Hannah Pliner and Chris Letson and Peter Heutink and Maria Martinez and Thomas Gasser and Traynor, {Bryan J.} and Nick Wood and John Hardy and Singleton, {Andrew B.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1016/j.neurobiolaging.2014.07.028",
language = "English",
volume = "36",
pages = "1605.e7--e12",
journal = "Neurobiology of Aging",
issn = "0197-4580",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases

AU - International Parkinson's Disease Genomics Consortium (IPDGC) and the Parkinson's Disease meta-analysis consortium

AU - Nalls, Mike A.

AU - Bras, Jose

AU - Hernandez, Dena G.

AU - Keller, Margaux F.

AU - Majounie, Elisa

AU - Renton, Alan E.

AU - Saad, Mohamad

AU - Jansen, Iris

AU - Guerreiro, Rita

AU - Lubbe, Steven

AU - Plagnol, Vincent

AU - Gibbs, J. Raphael

AU - Schulte, Claudia

AU - Pankratz, Nathan

AU - Sutherland, Margaret

AU - Bertram, Lars

AU - Lill, Christina M.

AU - DeStefano, Anita L.

AU - Faroud, Tatiana

AU - Eriksson, Nicholas

AU - Tung, Joyce Y.

AU - Edsall, Connor

AU - Nichols, Noah

AU - Brooks, Janet

AU - Arepalli, Sampath

AU - Pliner, Hannah

AU - Letson, Chris

AU - Heutink, Peter

AU - Martinez, Maria

AU - Gasser, Thomas

AU - Traynor, Bryan J.

AU - Wood, Nick

AU - Hardy, John

AU - Singleton, Andrew B.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Our objective was to design a genotyping platform that would allow rapid genetic characterization of samples in the context of genetic mutations and risk factors associated with common neurodegenerative diseases. The platform needed to be relatively affordable, rapid to deploy, and use a common and accessible technology. Central to this project, we wanted to make the content of the platform open to any investigator without restriction. In designing this array we prioritized a number of types of genetic variability for inclusion, such as known risk alleles, disease-causing mutations, putative risk alleles, and other functionally important variants. The array was primarily designed to allow rapid screening of samples for disease-causing mutations and large population studies of risk factors. Notably, an explicit aim was to make this array widely available to facilitate data sharing across and within diseases. The resulting array, NeuroX, is a remarkably cost and time effective solution for high-quality genotyping. NeuroX comprises a backbone of standard Illumina exome content of approximately 240,000 variants, and over 24,000 custom content variants focusing on neurologic diseases. Data are generated at approximately $50-$60 per sample using a 12-sample format chip and regular Infinium infrastructure; thus, genotyping is rapid and accessible to many investigators. Here, we describe the design of NeuroX, discuss the utility of NeuroX in the analyses of rare and common risk variants, and present quality control metrics and a brief primer for the analysis of NeuroX derived data.

AB - Our objective was to design a genotyping platform that would allow rapid genetic characterization of samples in the context of genetic mutations and risk factors associated with common neurodegenerative diseases. The platform needed to be relatively affordable, rapid to deploy, and use a common and accessible technology. Central to this project, we wanted to make the content of the platform open to any investigator without restriction. In designing this array we prioritized a number of types of genetic variability for inclusion, such as known risk alleles, disease-causing mutations, putative risk alleles, and other functionally important variants. The array was primarily designed to allow rapid screening of samples for disease-causing mutations and large population studies of risk factors. Notably, an explicit aim was to make this array widely available to facilitate data sharing across and within diseases. The resulting array, NeuroX, is a remarkably cost and time effective solution for high-quality genotyping. NeuroX comprises a backbone of standard Illumina exome content of approximately 240,000 variants, and over 24,000 custom content variants focusing on neurologic diseases. Data are generated at approximately $50-$60 per sample using a 12-sample format chip and regular Infinium infrastructure; thus, genotyping is rapid and accessible to many investigators. Here, we describe the design of NeuroX, discuss the utility of NeuroX in the analyses of rare and common risk variants, and present quality control metrics and a brief primer for the analysis of NeuroX derived data.

KW - Genetics

KW - Genotyping

KW - Imputation

KW - Meta-analysis

KW - Methods

KW - Neurodegeneration

KW - Parkinson's

UR - http://www.scopus.com/inward/record.url?scp=84923445949&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923445949&partnerID=8YFLogxK

U2 - 10.1016/j.neurobiolaging.2014.07.028

DO - 10.1016/j.neurobiolaging.2014.07.028

M3 - Article

VL - 36

SP - 1605.e7-e12

JO - Neurobiology of Aging

JF - Neurobiology of Aging

SN - 0197-4580

IS - 3

ER -